Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Sorafenib 3cabozantinib 2vandetanib 1temsirolimus 1pembrolizumab 1lenvatinib 1apatinib 1Vitamin B 12 1Thyrotropin-Releasing Hormone 1Pemetrexed 1Panobinostat 1Metformin 1Folic Acid 1Fluorescein 1Everolimus 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Diseases × temsirolimus × Clear all
NCT01025453 2018-08-15

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
37 enrolled 11 charts
Head & Neck

Thyroid Diseases, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡